1. Agewall S, Kendall M (1997) Treatment with β-blockers — the value of an even plasma concentration over 24 h. J Clin Pharm Ther 22: 171–179
2. Andersson B, Åberg J (1999) The effect on heart rate of immediate and slow-release metoprolol in patients with chronic heart failure (Abstract). J Am Coll Cardiol 33: 183A–184A
3. Blomqvist I, Westergren G, Sandberg A, Jonsson UE, Lundborg P (1988) Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol. Eur J Clin Pharmacol 33 (Suppl): S19-S24
4. Hjalmarson Å, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf Di, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus K-L, Janosi A, Thorgeirsson G, Dunselman PHJM, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P for the MERIT-HF study Group (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 283: 1295–1302
5. Hjalmarson Å, Olsson G, Bondjers G, Dahlöf C, Sandberg A, Åblad B, Wiklund I, Wikstrand J (1996) Cardioselective β-adrenoreceptor blockers. Metoprolol. In: Messerli FH (Ed) Cardiovascular Drug Therapy. W.B. Saunders Co, Philadelphia, USA, pp 522–540